NAMS newamsterdampharma.com Earnings growth forecast for next year

Corporate emblem and logo of NewAmsterdam Pharma Company N.V. (NAMS)

The earnings per share forecast for next year demonstrates that the current parameter is -28.40. NewAmsterdam Pharma (NAMS) business development relies on the success of clinical trials and regulatory approvals. Stable free cash flow is ensured by patent protection within the metabolic pathology niche. Meanwhile, the active R&D phase for the CETP inhibitor guarantees the company a strong position in the cardiology sector.

NewAmsterdam Pharma N.V. (NAMS): Expected net earnings per share growth next year from 06/21/2023 to 11/17/2026

NAMS (NewAmsterdam Pharma Company): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:NAMS, newamsterdampharma.com
Finished products of NewAmsterdam Pharma Company N.V.

During fundamental asset screening, this indicator serves as a leading signal of market expectations for earnings per share. By analyzing the expected EPS growth for the coming year, an investor can observe a smoothed vector of consensus forecasts, which for NewAmsterdam Pharma (NAMS) directly reflects the potential commercial success of obicetrapib as an affordable alternative to injectable methods for treating hypercholesterolemia.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|SLNO: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio Pharma|Agios Corp (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year